Diagnostic Problems of a Male Patient with Mixed Connective Tissue Disease

Nina Oktafianti Marfu’ah¹, Awalia²*
¹Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Hospital Surabaya, Indonesia.
²Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Hospital Surabaya, Indonesia.

ABSTRACT
Mixed connective tissue disease (MCTD) is an overlap disease, recognized as an entity disease with a mixture of clinical manifestations from systemic lupus erythematosus (SLE), systemic sclerosis (SSc), polymyositis/dermatomyositis, and rheumatoid arthritis, accompanied by the presence of high titers antibodies to U1 ribonucleoprotein (anti-U1RNP). We had reported a case of a male patient who had chronic dysphagia, progressive dyspnea, and the presence of skin lesions. The examination found chronic dysphagia, progressive dyspnea caused by pneumonia and suspected interstitial lung disease, autoimmune hemolytic anemia, discoid lesions, and skin biopsy revealed scleroderma. This patient did not meet the diagnostic criteria of MCTD because anti-U1RNP examination had not been performed as one of the diagnostic criteria’ requirements. However, because he has vital signs and symptoms toward MCTD where there were overlapping symptoms of SLE and SSc symptoms, we diagnosed him as MCTD.

Keywords: Connective tissue disease, autoimmune, U-RNP antibody.

Correspondence: Awalia
E-mail: awalia_nov74@yahoo.com

Article history: • Received 21 December 2020 • Accepted 27 January 2021

INTRODUCTION
There are six autoimmune connective tissue diseases, which are characterized by the presence of autoantibodies and autoimmune-mediated organ damage, including systemic lupus erythematosus (SLE), systemic sclerosis/scleroderma (SSc/ScI), polymyositis (PM), dermatomyositis (DM), rheumatoid arthritis (RA), and Sjogren’s syndrome (SS) (Bennett, 2017). Mixed connective tissue disease (MCTD) is an overlap disease, has been recognized as an entity disease with a mixture of clinical manifestations from SLE, SSc, PM/DM, and RA, accompanied by the presence of U1-Ribonucleoprotein antibodies (anti-U1-RNP) in high titers (Ortega-Hernandez & Shoenfeld, 2012; Tendean et al., 2018). The prevalence of MCTD in the Indian/Alaska America is 6.4 per 100,000 population (Ferucci et al., 2017). In Japan, 2.7 patients per million population are reported (Tendean et al., 2018). The mean age of onset was 31.9 years, and more than three-quarters of patients were females. This confirms the disease’s rarity and predilection for the female sex (Katewa et al., 2014).

Here we present a rare case of a male patient with chronic dysphagia, progressive dyspnea, skin lesions, and autoimmune hemolytic anemia (AIHA). Furthermore, this patient was diagnosed with MCTD.

CASE REPORT
A man, 52 years old, came to our hospital with chief complaints of shortness of breath and difficulty in swallowing. Since the last two months, the complaint of shortness of breath occurred both during activity and rest, then became worse since last week, and productive cough since last week. There was no complaint of fever. He also complained of difficulty swallowing for the last eight months and became worse for three months. He has been given refined food through a nasogastric tube (NGT) to facilitate feeding since last month. He experienced hoarse sounds for six months. There was no complaint of bluish or pale of the fingers when exposed to cold water. He felt the skin on his hands and feet tight since last two months.

It was found in the past medical history since eighteen months ago that the patient experienced a complaint of reddish skin accompanied by scaly and flaking skin on the face and neck area. Besides, there was joint pain in the lower back, waist, wrists, legs, fingers, and toes. Joint pain existed, especially after waking up and feels better during the day after activity. He also complained of frequent hair fall, sometimes mouth ulcers, and redness on the face increases when exposed to sunlight. At that time, he was diagnosed with psoriasis arthritis by a rheumatologist, then received methylprednisolone and sulfasalazine. Because there was no improvement, sulfasalazine was replaced with mycophenolate
The laboratory results: Hb 9.6 g/dL, WBC 12,600/μL, 91% lymphocytes, 2.7% platelets 77,000/μL, reticulocytes 1.08%, albumin 2.2 g/L, sodium 129 mmol/L, potassium 4.4 mmol/L, CRP 8.6 mg/dL, C3: 39 mg/L, C4: 24.4 mg/dL, non-reactive HIV, smear sputum: gram-negative bacteria, sputum culture: Pseudomonas aeruginosa. He was given intravenous methylprednisolone 1 mg/body weight, oral MMF 2x360 mg, and antibiotic. He was planned to pulse dose of methylprednisolone and cyclophosphamide if the infection had been resolved.

On the 6th of care: Shortness of breath become worse, BP 100/60 mmHg, HR 110 beat/minute, RR 28 times/minute, temperature 36.80C, SO2 97% (non-rebreathing mask). Dyspnea was found, and ronchi in both basal lungs. Laboratory of BGA: PH 7.28, PCO2 77, PO2 107, HCO3 36, BE 9.5, SO2 97%. The skin biopsy was suggesting scleroderma. He suffered respiratory failure, therefore was planned for a ventilator. However, he refused the ventilator.

On the 7th day of care: Shortness of breath worsened, GCS E3V3M5, BP 80/50 mmHg, HR 120 beat/minute, RR 30 times/minute, SO2 90-93%. The patient had not been tested for anti-U1-RNP because of limited funds. He eventually died because of septic shock and respiratory failure.

DISCUSSION

The initial presentation of the MCTD patients usually comprises nonspecific signs such as swollen digits, arthralgia, myalgia or muscle weakness, acid reflux or dysphagia, Raynaud’s phenomenon, shortness of breath, general malaise, and fatigue (Katewa et al., 2014). MCTD can be a severe disease with the development of pulmonary arterial hypertension (PAH), glomerulonephritis, vasculitis, gastrointestinal bleeding, and severe central nervous involvement, which does not always have a good prognosis (Ortega-Hernandez & Shoenfeld, 2012). The basic premise of the MCTD concept and included in the main diagnostic criteria is the presence of anti-U1-RNP antibodies. Other investigations that can be done to assess the involvement of specific organs in the MCTD include routine blood tests, urinalysis, creatine phosphokinase, radiographic of arthritis joints, chest X-ray, electrocardiography, and echocardiography. Echocardiography is the most useful screening test for PAH (Bennett, 2017). Pulmonary functions should be monitored in MCTD because the pulmonary disease is common and the most frequent disease-associated cause of death. High-resolution CT (HRCT) of the chest may be indicated to assess ILD when abnormalities are found on plain-film radiographs or pulmonary function testing (Hoffman & Greidinger, 2013). There are four diagnostic criteria for MCTD, such as Sharp criteria, Alarcon-Segovia, Kasukawa, and Kahn&Appeboom’s. A comparative study comparing all four criteria reported that the criteria for Alarcon-Segovia or pulmonary function testing (Hoffman & Greidinger, 2013).

This patient had clinical signs and symptoms, such as difficulty swallowing, worsening shortness of breath, the skin that feels tight, and AIHA. These were felt after he did not take MMF drug since last three months. Past medical history, he has reddish and scaly skin accompanied by joint pain, frequent hair fall, and oral ulcer. At that time, he was diagnosed with psoriatic arthritis and received immunosuppressants, but he did not take immunosuppressants for the last three months. Physical examination revealed anemia, dyspnea, dysphagia, ronchi in the basal lung, salt and pepper appearance, atherosclerosis, and discoid lesions. Laboratory tests revealed anemia, lymphopenia,
hypoalbuminemia, hyponatremia, and decreased C3. Serological results of ANA profile revealed negative (during taking immune-suppressant for six months). These negative serological results could also result from false negatives because the patient was examined while taking immune-suppressant. The DCT was positive (when the patient did not take immune-suppressant for three months). Chest X-ray revealed pleural effusion and reticular pattern in both lungs, suggesting diffuse ILD. Sputum cultures revealed Pseudomonas aeruginosa. Skin biopsy revealed scleroderma. The patient was planned for esophagogastroduodenoscopy, echocardiography, and chest CT, but he did not have the opportunity to do because he died before the examination schedule.

The serology of patients with autoimmune diseases can produce negative results despite showing clear signs and symptoms of the disease. This can be due to the influence of antigenic deficiency in a testing substrate, concurrent immunosuppressive treatment, or persistent profound proteinuria associated with IgG loss through the kidneys. All of these can cause spuriously negative serological test results (Mugunthan, 2005). An elevated anti-U1-RNP is one of the diagnostic criteria of MCTD. The patient did not undergo the test because of limited funds. However, due to the presence of overlapping symptoms between SLE (arthritis with synovitis, discoid lesions, AIHA, decreasing C3, lymphopenia) and SSc (acrosclerosis, chronic dysphagia, suspicion of ILD, salt and pepper appearance, and skin biopsy revealed scleroderma), we diagnosed this patient as MCTD.

Recently, there were no specific recommended guidelines for the treatment of MCTD. Immunosuppressive and steroid are still the primary therapy for MCTD. The therapy principle is based on clinical manifestations that appear in patients (Tendean et al., 2018). The leading cause of death in patients with MCTD is PAH (Hajas et al., 2013). In a cohort study, it was found that the MCTD phenotype was stable in the majority of patients, but a small proportion of patients who were initially diagnosed with MCTD could develop to other connective tissue diseases. Of the 118 patients, 9% of MCTD developed to SLE, RA, and SSC in 17 years. Long-term remission in MCTD is not frequent. However, the disease course tends to be milder compared to SLE and SSC (Reiseter et al., 2017). These patients were given supplemental oxygen, antibiotics for pneumonia, corticosteroids, and MMF. He was planned for pulse dose corticosteroid and cyclophosphamide if the infection had been resolved, but this was not given because he died because of septic shock and respiratory failure.

CONCLUSION
We had reported a case of a 52-year-old man with chronic dysphagia, progressive dyspnea caused by pneumonia and suspected ILD, AIHA, discoid lesions, and skin biopsy revealed scleroderma. This patient did not meet the diagnostic criteria of MCTD because an anti-U1RNP examination had not been performed as one of the requirements. However, because he had vital signs and symptoms toward MCTD, so this patient was diagnosed as MCTD.

CONFLICT OF INTEREST
The author declare there is no conflict of interest of this study.